Aurinia Pharmaceuticals (AUPH) Current Assets (2016 - 2026)

Aurinia Pharmaceuticals (AUPH) has 11 years of Current Assets data on file, last reported at $480.2 million in Q1 2026.

• Quarterly Current Assets rose 18.36% year-over-year to $480.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $480.2 million (up 18.36% YoY) and the FY2025 annual result came in at $492.0 million, up 10.16% from the prior year.
• Current Assets slipped to $480.2 million in Q1 2026, from $492.0 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $492.0 million in Q4 2025 to a low of $398.2 million in Q1 2024.
• A 5-year average of $437.9 million and a median of $438.7 million in 2025 frame the typical range for Current Assets.
• The widest YoY moves for Current Assets: up 39.63% in 2022, down 13.79% in 2022.
• Tracing AUPH's Current Assets over 5 years: stood at $442.5 million in 2022, then slipped by 4.01% to $424.8 million in 2023, then advanced by 5.13% to $446.6 million in 2024, then climbed by 10.16% to $492.0 million in 2025, then dropped by 2.38% to $480.2 million in 2026.
• The last three Current Assets figures came in at $480.2 million (Q1 2026), $492.0 million (Q4 2025), and $438.7 million (Q3 2025), per Business Quant data.